Session Type
Date Time
Local Date Time

The HIV epidemic, now in its fourth decade, has affected 75.7 million people, led to 32.7 million deaths, disproportionally affecting vulnerable populations and costing an estimated US $41.2 billion. Tremendous progress has been made in developing effective treatments and prevention options but the challenge of developing a safe and effective HIV vaccine persists, raising important questions about where an HIV vaccine should feature in our global efforts to end the epidemic. Co-sponsored by the Global HIV Vaccine Enterprise at IAS and UNAIDS, this satellite will start by reaffirming the case for an HIV vaccine against a background of effective but not yet broadly accessible or acceptable prevention. Through a panel discussion and audience participation, we will look to a future in which we have discovered an HIV vaccine – and ask critical questions such as who we should immunize, what would the regimen look like, what would be the costs and the benefits and who should pay for it.

7 min
Welcome and Introduction
Lucy STACKPOOL-MOORE, International AIDS Society, Switzerland
Susan BUCHBINDER, United States
10 min
Why an HIV vaccine?
Kevin DE COCK, UNAIDS, Switzerland
17 min
The Year is 2025: What would a vaccine look like?
Gabriela GOMEZ, Sanofi, United Kingdom
49 min
Panel discussion
Kundai CHINYENZE, IAVI, United Kingdom
Rachel BAGGALEY, Switzerland
Daisy OUYA, AVAC, Kenya
Jerome SINGH, University of KwaZulu-Natal, South Africa
Paul STOFFELS, Johnson & Johnson, United States
Yazdan YAZDANPANAH, ANRS - Maladies infectieuses émergentes, France
Lucy STACKPOOL-MOORE, International AIDS Society, Switzerland
Kevin DE COCK, UNAIDS, Switzerland
Gabriela GOMEZ, Sanofi, United Kingdom
7 min
Eamonn MURPHY, UNAIDS, Switzerland